Abstract
Abstract: :
Purpose: To assess in a clinical human trial the safety of intravitreal silicone oil/ acetylsalicylic acid suspension (AS SiO) for proliferative vitreoretinopathy. Methods and Patients: Medical grade silicone oil was suspended with acetylsalicylic acid to a final concentration of 0.4 mg/mL. After vitrectomy the acetylsalicylic acid/silicone oil suspension was injected intravitreously in 5 patients. The eyes presented with a visual acuity of ≤ 20/200 due to an extended history of retinal detachment and consecutive surgery because of either rhegmatogenous or traumatic retinal detachment. Inclusion criteria were the presence of proliferative vitreoretinopathy grade C, pseudophakia and a vision of ≥ 100/200 in the contralateral eye. Excluded were eyes with additional retinopathys and patients with hypertension, patients with a history of ulcers and patients with an allergy against NSAIDs. Removal of the AS SiO was carried out 6 months after injection in all eyes except for one eye that required reoperation due to redetachment. In this case the AS SiO was removed during the reoperation and pure silicone oil was injected . Results: During follow up the suspension stayed clear in all eyes. No hemorrhages in the anterior or posterior chamber were observed. The ocular tension stayed normal. No topical or systemic adverse effects occurred in our patients. Conclusions: The intravitreal tamponade with silicone oil/ acetylsalicylic acid suspension for proliferative vitreoretinopathy demonstrated its safety in the presented human trial. The number of 5 eyes is too small to draw conlusions in respect to its efficacy for the treatment of proliferative vitreoretinopathy but a prospective, randomized, double– blind multicenter study has been initiated 12 months ago.
Keywords: proliferative vitreoretinopathy • vitreous substitutes • vitreoretinal surgery